Physician profile
Peter V Choy
NPI 1164412177
$1,574.88
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $337 · 2021: $644 · 2022: $127 · 2023: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $623.58 | 2019-2022 | |
| Abbvie INC. | $228.85 | 2021-2023 | Ubrelvy |
| Lilly USA, LLC | $116.99 | 2020-2023 | Jardiance, Emgality |
| Pfizer INC. | $101.05 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.71 | 2019-2021 | |
| Allergan, INC. | $85.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $70.48 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.06 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $46.92 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $44.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $39.95 | 2020 | |
| Biogen, INC. | $21.86 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.86 | 2023 | Quviviq |
| Amarin Pharma, INC. | $20.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Choy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.